SuperworthKestra Medical Technologies KMTS
- Market cap
- $1.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 16.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $106.7M
- +61% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −7.2%
Kestra Medical Technologies trades at 16.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $106.7M over the last twelve months, up 61% on a year earlier.
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|
| $12.8M | $14.7M | $15.1M | $17.2M | $19.4M+52% | $22.6M+53% | $24.6M+63% | $28.6M+66% | $31M+60% | |
| Cost of revenue | $8.6M | $8.9M | $8.5M | $9.6M | $10.5M+23% | $11.1M+26% | $11.6M+36% | $13M+35% | $13.5M+28% |
| Gross profit | $4.2M | $5.8M | $6.5M | $7.6M | $8.9M+111% | $11.4M+96% | $12.9M+97% | $15.7M+106% | $17.5M+98% |
| R&D | $3.4M | $3.5M | $3.4M | $5.4M | $4M+18% | $4.9M+39% | $5M+48% | $5.6M+5% | $6.8M+70% |
| SG&A | $19.2M | $21.5M | $23.8M | $50.5M | $33.7M+75% | $38.3M+79% | $42.7M+79% | $49.4M−2% | $48.4M+43% |
| −$18.4M | −$19.1M | −$20.6M | −$48.2M | −$28.9M+57% | −$31.8M+66% | −$34.8M+69% | −$39.3M−18% | −$37.7M+30% | |
| Interest expense | $1.9M | $2.3M | $1.8M | $1.8M | $1.9M+2% | $1.9M−18% | $1.9M+6% | $1.8M+5% | $1.9M+1% |
| Pre-tax income | −$20.3M | −$20.6M | −$21.7M | −$51M | −$25.8M+27% | −$32.8M+59% | −$34.1M+57% | −$38.6M−24% | −$44M+71% |
| $7K | $8K | $18K | $102K | $33K+371% | $34K+325% | $35K+94% | $192K+88% | $50K+52% | |
| Net income | −$19.9M | −$20.4M | −$21.5M | −$52.1M | −$25.8M+30% | −$32.8M+61% | −$34.2M+59% | −$38.8M−25% | −$44.1M+71% |
| −$1.12 | −$1.19 | −$1.25 | −$1.41 | −$0.50−55% | −$0.64−46% | −$0.61−51% | −$0.67−53% | −$0.75+50% | |
| 19.9M | 19.9M | 19.9M | 39.2M | 51.3M+158% | 51.4M+158% | 55.8M+181% | 58.3M+49% | 58.6M+14% |
EPS, diluted: Q4 FY25 and Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY25 and Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Kestra Medical Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KMTSKestra Medical Technologies | $1.7B | n/m | n/a | 16.1× | +61% | n/m | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| Peer median | $1.7B | 34.4× | 47.7× | 3.4× | +11% | 7.3% |
More on Kestra Medical Technologies
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .